{"id":"NCT00145470","sponsor":"Organon and Co","briefTitle":"12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)","officialTitle":"A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06-02","primaryCompletion":"2007-02-28","completion":"2007-03-22","firstPosted":"2005-09-05","resultsPosted":"2019-09-16","lastUpdate":"2024-05-21"},"enrollment":326,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Asenapine","otherNames":["Org 5222"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Asenapine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 12-week study that will test the safety and efficacy of asenapine when used in addition to lithium or valproate for subjects with acute manic or mixed episodes of Bipolar I Disorder.","primaryOutcome":{"measure":"Least Squares Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Score at Day 21","timeFrame":"Baseline and Day 21","effectByArm":[{"arm":"Placebo","deltaMin":28.2,"sd":0.45},{"arm":"Asenapine","deltaMin":27.9,"sd":0.46}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0257"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22198448"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":166},"commonTop":["Headache","Insomnia","Sedation","Somnolence","Nausea"]}}